Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1
- 저널
- AMERICAN JOURNAL OF CARDIOLOGY105(6) · pp.813 · 2010
- 피인용
- Web of Science 16
- JCR IF
- JCR 2009 3.575
- ISSN
- 0002-9149
저자
- Kim, Hyun Kuk제1저자전남대학교, KO
- Jeong, Myung Ho전남대학교, KO
- Ahn, Young Keun전남대학교, KO
- Kim, Jong Hyun수영한서병원, KO
- Chae, Shung Chull경북대학교, KO
- Kim, Young Jo영남대학교, KO
- Hur, Seung Ho계명대학교, KO
- Seong, In Whan충남대학교, KO
- 홍택종부산대학교, 의과대학, 의학과, 내과학교실, KO
- Choi, Dong Hoon연세대학교, Severans Hosp, KO
- Cho, Myeong Chan충북대학교, KO
- Kim, Chong Jin경희대학교, KO
- Seung, Ki Bae가톨릭대학교, KO
- Chung, Wook Sung가톨릭대학교, KO
- Jang, Yang Soo연세대학교, KO
- Rha, Seung Woon고려대학교, KO
- Bae, Jang Ho건양대학교, KO
- Cho, Jeong Gwan전남대학교, KO
- Park, Seung Jung울산대학교, KO
초록
Zotarolimus-eluting stents (ZESs) demonstrated greater in-segment late luminal loss and in-segment binary restenosis rates compared to sirolimus-eluting stents (SESs) in several studies. However, no data are available in direct comparison between the clinical outcomes of the 2 stents in unselected patients with ST-segment elevation acute myocardial infarction (STEMI). The aim of the present study was to compare the clinical outcomes of ZESs and SESs in real-world patients with STEMI. A total of 873 patients with STEMI (306 patients in the ZES group and 567 patients in the SES group) were enrolled in a nationwide prospective Korea Acute Myocardial Infarction Registry (KAMIR) from January 2007 to January 2008. The primary end points were major adverse cardiac events, a composite of all causes of death, myocardial infarction, and target lesion revascularization during a 12-month clinical follow-up. During 1 year of follow-up, the primary end points occurred in 140 patients (16.0%). The use of glycoprotein IIb/IIIa inhibitors and the occurrence of multivessel disease were more common in the SES group. The SES group had a significantly lower incidence of major adverse cardiac events (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.07 to 2.16, p = 0.02), target lesion revascularization (HR 2.16, 95% Cl 1.01 to 4.59, p = 0.046), and target vessel revascularization (HR 2.24, 95% CI 1.18 to 4.24, p = 0.013). However, no significant differences were found in death or myocardial infarction (HR 1.37, 95% CI 0.91 to 2.05, p = 0.129). In conclusion, SESs provided superior angiographic outcomes, translating into better clinical outcomes and negating any change in STEMI patient safety profiles compared to ZESs. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:813-818)
키워드
식별자
- WoS UID
- 000278137300009



로그인
연구물 목록으로